

Martin F Kaiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4156662/publications.pdf>

Version: 2024-02-01

114
papers

4,830
citations

136740

32
h-index

106150

65
g-index

117
all docs

117
docs citations

117
times ranked

6041
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3911-3920.	0.8	463
2	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. <i>Nature Communications</i> , 2015, 6, 6997.	5.8	261
3	Intracлона heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014, 28, 384-390.	3.3	252
4	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 57-73.	5.1	245
5	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019, 291, 5-13.	3.6	209
6	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	6.3	187
7	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e370-e380.	2.2	170
8	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2013, 122, 219-226.	0.6	147
9	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146
10	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
11	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
12	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. <i>Lancet Haematology</i> , the, 2021, 8, e389-e392.	2.2	121
13	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
14	Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. <i>British Journal of Haematology</i> , 2020, 190, e83-e86.	1.2	92
15	The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. <i>Nature Genetics</i> , 2013, 45, 522-525.	9.4	91
16	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	5.8	86
17	Whole body diffusion weighted <sc>MRI</sc> â€“ a new view of myeloma. <i>British Journal of Haematology</i> , 2015, 171, 29-37.	1.2	80
18	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. <i>Lancet Haematology</i> , the, 2019, 6, e154-e166.	2.2	71

#	ARTICLE	IF	CITATIONS
19	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. <i>Blood</i> , 2014, 123, 3414-3419.	0.6	68
20	Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. <i>Leukemia</i> , 2018, 32, 2459-2470.	3.3	68
21	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019, 104, 1440-1450.	1.7	67
22	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
23	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020, 136, 1091-1104.	0.6	58
24	Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. <i>Blood</i> , 2014, 124, 2467-2468.	0.6	57
25	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020, 34, 604-612.	3.3	56
26	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
27	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , 2018, 32, 1727-1738.	3.3	50
28	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021, 11, 40.	2.8	46
29	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. <i>Haematologica</i> , 2021, 106, 2754-2758.	1.7	45
30	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e616-e629.	2.2	42
31	Mutational processes contributing to the development of multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 60.	2.8	41
32	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
33	Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 134-137.	0.2	35
34	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. <i>Oncogene</i> , 2019, 38, 3216-3231.	2.6	33
35	Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. <i>Nature Communications</i> , 2016, 7, 13656.	5.8	32
36	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	2.8	32

#	ARTICLE	IF	CITATIONS
37	A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 91-98.	1.5	31
38	Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. <i>Nature Communications</i> , 2016, 7, 10290.	5.8	31
39	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. <i>Scientific Reports</i> , 2017, 7, 41071.	1.6	31
40	Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. <i>European Radiology</i> , 2018, 28, 1687-1691.	2.3	29
41	Subclonal TP53 copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , 2018, 132, 2465-2469.	0.6	29
42	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. <i>Journal of Clinical Oncology</i> , 2022, 40, 2889-2900.	0.8	29
43	Search for multiple myeloma risk factors using Mendelian randomization. <i>Blood Advances</i> , 2020, 4, 2172-2179.	2.5	27
44	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020, 34, 3091-3096.	3.3	26
45	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 551-555.	1.2	25
46	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
47	Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021, 35, 2043-2053.	3.3	23
48	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
49	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. <i>Radiology Imaging Cancer</i> , 2021, 3, e210048.	0.7	22
50	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2506-2506.	0.8	22
51	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
52	Neutral tumor evolution in myeloma is associated with poor prognosis. <i>Blood</i> , 2017, 130, 1639-1643.	0.6	20
53	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	20
54	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2022, 107, 2408-2417.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003454.	3.9	18
56	MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021, 11, e046225.	0.8	18
57	Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. <i>Cell Reports</i> , 2017, 20, 2556-2564.	2.9	17
58	Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. <i>Scientific Reports</i> , 2015, 5, 12473.	1.6	16
59	Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. <i>BMC Cancer</i> , 2017, 17, 718.	1.1	16
60	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
61	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	1.7	16
62	Whole-Body Imaging in Multiple Myeloma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 509-525.	0.6	15
63	Preclinical toxicology and safety pharmacology of the first-in-class GADD45 ² /MKK7 inhibitor and clinical candidate, DTP3. <i>Toxicology Reports</i> , 2019, 6, 369-379.	1.6	15
64	Clinical proof of concept for a safe and effective <i>scp</i> >NF</scp>â€”Bâ€”targeting strategy in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 588-592.	1.2	15
65	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8005-8005.	0.8	15
66	The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a â€œreal-worldâ€”study: the Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2017, 58, 494-497.	0.6	14
67	Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. <i>Human Genomics</i> , 2019, 13, 37.	1.4	14
68	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, openâ€”label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021, 192, 853-868.	1.2	14
69	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. <i>Blood</i> , 2019, 134, 1865-1865.	0.6	14
70	The genomic landscape of plasma cells in systemic light chain amyloidosis. <i>Blood</i> , 2018, 132, 2775-2777.	0.6	12
71	Exposureâ€”Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 614-627.	1.0	12
72	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 667-675.	0.2	12

#	ARTICLE	IF	CITATIONS
73	An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. <i>Blood Cancer Journal</i> , 2020, 10, 101.	2.8	11
74	Redefining nonmeasurable multiple myeloma using mass spectrometry. <i>Blood</i> , 2022, 139, 946-950.	0.6	11
75	Intensity-adjusted therapy in non-transplant ineligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022, 12, e056147.	0.8	11
76	Positive selection as the unifying force for clonal evolution in multiple myeloma. <i>Leukemia</i> , 2021, 35, 1511-1515.	3.3	10
77	Functional dissection of inherited non-coding variation influencing multiple myeloma risk. <i>Nature Communications</i> , 2022, 13, 151.	5.8	10
78	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. <i>Magnetic Resonance Imaging</i> , 2021, 75, 60-64.	1.0	9
79	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018, 132, 301-301.	0.6	9
80	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015, 126, 4263-4263.	0.6	9
81	Impact of mitochondrial DNA mutations in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 46.	2.8	8
82	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial. <i>Blood</i> , 2021, 138, 465-465.	0.6	8
83	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. <i>Blood Cancer Journal</i> , 2022, 12, 52.	2.8	8
84	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. <i>BMC Hematology</i> , 2016, 16, 14.	2.6	7
85	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. <i>British Journal of Radiology</i> , 2019, 92, 20180822.	1.0	6
86	Germline variants at SOHLH2 influence multiple myeloma risk. <i>Blood Cancer Journal</i> , 2021, 11, 76.	2.8	6
87	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). <i>Haematologica</i> , 2021, 106, 2694-2706.	1.7	6
88	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7588-TPS7588.	0.8	6
89	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018, 2, 2400-2411.	2.5	5
90	A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple myeloma patients. <i>British Journal of Haematology</i> , 2020, 191, 927-930.	1.2	5

#	ARTICLE	IF	CITATIONS
91	Reference bias in the Illumina Isaac aligner. <i>Bioinformatics</i> , 2020, 36, 4671-4672.	1.8	5
92	Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival – Data from the Ukmrc Myeloma XI Trial. <i>Blood</i> , 2018, 132, 122-122.	0.6	5
93	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019, 134, 1906-1906.	0.6	5
94	A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial. <i>Blood</i> , 2016, 128, 3321-3321.	0.6	5
95	A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex. <i>PLoS ONE</i> , 2014, 9, e99493.	1.1	5
96	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	1.3	5
97	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	0.8	4
98	Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. <i>British Journal of Haematology</i> , 2020, 189, e1-e3.	1.2	4
99	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. <i>Trials</i> , 2020, 21, 826.	0.7	3
100	Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. <i>Blood Advances</i> , 2022, 6, 5113-5123.	2.5	3
101	Regions of homozygosity as risk factors for multiple myeloma. <i>Annals of Human Genetics</i> , 2019, 83, 231-238.	0.3	2
102	An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e65-e67.	0.7	2
103	Improving real-world myeloma patient access to whole body MRI through –open-access–knowledge sharing: The UK experience. <i>EJHaem</i> , 2020, 1, 361-363.	0.4	2
104	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). <i>Blood</i> , 2019, 134, 3162-3162.	0.6	2
105	Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial. <i>Blood</i> , 2019, 134, 1889-1889.	0.6	2
106	High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in-Vitro Research. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1179-1188.	1.2	2
107	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. <i>Blood</i> , 2015, 126, 1847-1847.	0.6	1
108	Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
109	Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma. Blood, 2013, 122, 398-398.	0.6	0
110	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. Blood, 2015, 126, 4173-4173.	0.6	0
111	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	0.6	0
112	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. Blood, 2018, 132, 2000-2000.	0.6	0
113	Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients. Blood, 2021, 138, 2907-2907.	0.6	0
114	The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse. Blood, 2021, 138, 2683-2683.	0.6	0